exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089026 RNA Name: hsa-miR-520a-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53690933 End Site(bp): 53690954 External Links: hsa-miR-520a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand SEMA3C chr7 80742538 80922359 - APP chr21 25880550 26171128 - IKZF4 chr12 56007659 56038435 + MAGI3 chr1 113390515 113685923 + HTD2 chr3 58306262 58318574 + RPP14 chr3 58306247 58324695 + CELF2 chr10 10798397 11336675 + SLC7A2 chr8 17497088 17570573 + SYAP1 chrX 16719612 16765340 + FYCO1 chr3 45917899 45995824 - PDRG1 chr20 31944337 31952046 - OCRL chrX 129539849 129592561 + CLIP4 chr2 29097705 29189643 + COL4A2 chr13 110305812 110513209 + CDK6 chr7 92604921 92836594 - PLAGL2 chr20 32192504 32207743 - CLCN6 chr1 11806096 11848079 + MNT chr17 2384073 2401104 - XRRA1 chr11 74807739 74949200 - ZFAND4 chr10 45615500 45672780 - CCDC93 chr2 117915478 118014133 - UCHL1 chr4 41256413 41268455 + MSL1 chr17 40121971 40136917 + RACGAP1 chr12 49976923 50033136 - KIAA1522 chr1 32741830 32774970 + BTN3A1 chr6 26402237 26415208 + MBP chr18 76978827 77133683 - RGMA chr15 93035273 93089204 - CUL1 chr7 148697914 148801110 + TRIM37 chr17 58982638 59106921 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC125257.1 chr17 41848518 41851447 - AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.